Active substanceTaurineTaurine
Similar drugsTo uncover
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Dibicor®
    pills inwards 
    PIK-PHARMA, LLC     Russia
  • Igrele®
    drops d / eye 
    KVADRAT-S, LLC     Russia
  • CardioActiv® Taurine
    pills inwards 
    EVALAR, CJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    UPDATE OF PFC, CJSC     Russia
  • Taurine
    drops d / eye 
    VIFITEH, CJSC     Russia
  • Taurine
    solution
    DALHIMFARM, OJSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Firm VIPS-MED, LLC     Russia
  • Taurine
    films d / eye 
    Progress RCC, JSC     Russia
  • Taurine
    drops d / eye 
  • Taurine
    drops d / eye 
    Company DEKO, LLC     Russia
  • Taurine
    drops d / eye 
  • Taurin-Akos
    drops d / eye 
    SYNTHESIS, OJSC     Russia
  • Taurin-DIA
    drops d / eye 
  • Taurin-SOLOFARM
    drops d / eye 
    GROTEKS, LLC     Russia
  • Taufon
    drops d / eye 
  • Dosage form: & nbsppills
    Composition:

    Taurine 250 mg and excipients: microcrystalline cellulose 23 mg, potato starch 18 mg, gelatin 6 mg, silicon dioxide colloid (Aerosil) 0.3 mg, calcium stearate 2.7 mg.

    Description:

    Tablets are white or almost white in color,

    Plane cylindrical with a risk and chamfer.

    Pharmacotherapeutic group:metabolic means.
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Taurine is a natural product of the exchange of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, positively influences on phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in cells. Taurine revealed the properties of the inhibitory neurotransmitter, he possesses anti-stress action, can regulate the release of gamma-aminobutyric acid (G AMC), adrenaline, prolactin and other hormones, and to regulate the responses to them. By participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes, such as cytochromes, involved in the metabolism of various xenobiotics.

    Dibicor ® improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases, Dibicor ® increases blood flow and reduces the severity of cytolysis.Treatment with Dibicor® in cardiovascular insufficiency (CVS) leads to a reduction in stagnant phenomena in small and large circles of the circulation: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum rate of contraction and relaxation, indices of contractility and relaxation). The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and virtually no effect on blood pressure in patients with cardiovascular failure with low blood pressure. Dibikor® reduces side effects, the an overdose of cardiac glycosides and blockers of "slow" calcium channels; reduces the hepatotoxicity of antifungal agents. Raises the capacity for heavy physical exertion.

    When sugar diabetes approximately 2 weeks after the start of taking Dibicor®, the blood glucose concentration decreases. There was also a significant decrease concentrations triglycerides, to a lesser extent - concentration cholesterol, reduction of atherogenic plasma lipids. With prolonged use of the drug (about 6 months), improvement of the microcirculatory blood flow of the eye was noted.

    Pharmacokinetics:After a single dose of 500 mg of Dicicor, the active ingredient taurine After 15-20 minutes it is determined in the blood, reaching a maximum after 1.5-2 hours. Completely the drug is withdrawn after 24 hours.
    Indications:- cardiovascular insufficiency of various etiology;

    - intoxication caused by cardiac glycosides;

    - Type 1 diabetes mellitus;

    - Type 2 diabetes mellitus, including number and with moderate hypercholesterolemia;

    - as a hepatoprotector in patients taking antifungal drugs.

    Contraindications:

    Hypersensitivity to the drug. Age to 18 years (effectiveness and safety not established).

    Pregnancy and lactation:
    Dosing and Administration:

    With heart failure Dibicor® is taken internally by 250-500 mg (1-2 tablets) 2 times in day 20 minutes before meals, treatment - 30 days. The dose can be increased up to 2-3 g (8-12 tablets) per day or reduced to 125 mg (1/2 pills) appointment.

    In case of intoxication with cardiac glycosides - not less than 750 mg (3 tablets) per day.

    With type 1 diabetes mellitus 500 mg (2 tablets) 2 times a day in combination with insulin therapy in for 3-6 months.

    With type 2 diabetes mellitus 500 mg (2 tablets) 2 times a day in monotherapy or in combination with other hypoglycemic means for oral administration.

    With diabetes mellitus 2 type, including number of moderate hypercholesterolemia - 500 mg each (2 tablets) 2 times per day, course duration - by doctor's recommendations.

    As a hepatoprotector - 500 mg (2 tablets) 2 times per day in throughout the course of admission antifungal drugs.

    Side effects:

    Allergic reactions to the components of the drug are possible.

    Overdose:There is no information.
    Interaction:

    Dibicor can be used with other medicines; enhances the inotropic effect of cardiac glycosides.
    Special instructions:Against the background of taking Dibikor should reduce the dose of cardiac glycosides sometimes 2 times, depending on the sensitivity of patients to cardiac glycosides. The same rule applies to blockers of "slow" calcium channels.
    Effect on the ability to drive transp. cf. and fur:
    Form release / dosage:

    Tablets 250 mg. For 30 or 60 tablets in cans of orange glass. 10 tablets per contour cell pack. A jar or 3 or 6 contour squares, together with instructions for use, are placed in a cardboard box.

    Packaging:(10) - packings, cellular, outline (3) - packs, cardboard
    (10) - packings, cell planimetric (6) - packs cardboard
    Storage conditions:

    In a dry place protected from light at a temperature of no higher than 25 ° C.

    Keep out of the reach of children place.

    Shelf life:3 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:P N001698 / 01
    Date of registration:12.05.2008
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp05.09.2015
    Illustrated instructions
      Instructions
      Up